Exparel (bupivacaine Liposome recalls

The FDA has published 1 recall involving Exparel (bupivacaine Liposome since 2013. The latest was reported on 6 Mar 2013. Most were for potency & assay. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.

Total recalls1since 2013

Last 12 months0reported

Class I00% of total

Ongoing0latest 6 Mar 2013

Recalls per month, last 24 months

click a bar for that month

0Oct '24 0 0 0Jan '25 0 0 0Apr 0 0 0Jul 0 0 0Oct 0 0 0Jan '26 0 0 0Apr 0 0 0Jul 0 0

Severity split

Class I 0 0%Class II 1 100%Class III 0 0%

Why exparel (bupivacaine liposome is recalled

Potency & Assay1100%

Companies

Pacira Pharmaceuticals1100%

By year

20131100%

All exparel (bupivacaine liposome recalls, newest first

1 total

Reported	Class	Recall	Company	Reason	Where
6 Mar 2013Drug	CLASS II	Exparel (bupivacaine liposome injectable suspension) recalled	Pacira Pharmaceuticals	Potency & Assay	Nationwide

Should you stop taking Exparel (bupivacaine Liposome?

Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.